DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: LEMTRADA (Campath, alemtuzumab)
       *****************************************************
       #Post#: 3247--------------------------------------------------
       Impact of previous DMT on effectiveness, safety outcomes in PwMS
        treated w/Lemtrada
       By: agate Date: April 5, 2021, 7:17 pm
       ---------------------------------------------------------
       From the Journal of Neurology, Neurosurgery and Psychiatry
       (April 5,  2021), "Impact of previous disease-modifying
       treatment on effectiveness and safety outcomes, among patients
       with multiple sclerosis treated with alemtuzumab":
  HTML https://jnnp.bmj.com/content/early/2021/03/11/jnnp-2020-325304.long
       A summary of the findings is in Multiple Sclerosis News Today
       (April 5)--"Moving from Gilenya to Lemtrada May Not Be Optimal
       Choice, Study Says":
  HTML https://multiplesclerosisnewstoday.com/news-posts/2021/03/17/impact-of-previous-disease-modifying-treatment-on-effectiveness-and-safety-outcomes-among-patients-with-multiple-sclerosis-treated-with-alemtuzumab/
       *****************************************************